A dual approach to targeting tumour cell proliferation directly by inhibiting EGF activity, plus tumour vascularization by inhibiting VEGF activity is attractive, and studies of bevacizumab plus the EGFR TKI erlotinib have shown positive results in a second/third-line study of patients with NSCLC of non-squamous cell histology (Herbst et al, 2005). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.